Generated by AI
Burning Rock Biotech Ltd. ADR is a China-based cancer diagnostics company focused on next-generation sequencing solutions for precision oncology. The company develops and commercializes cancer therapy selection tests designed to help physicians identify genetic alterations and match patients with targeted treatment options. Its business also includes cancer early detection services and pharma research and development support, giving it a role across both clinical care and biopharmaceutical research. Burning Rock Biotech serves hospitals, laboratories, and pharmaceutical partners in China and the United States, with operations centered on molecular diagnostics and liquid biopsy applications. Through its testing platforms and oncology-focused laboratory services, the company contributes to the broader adoption of genomics in cancer care and the use of data-driven diagnostics in modern medicine.
WebsiteNo. 5, Xingdao Ring Road North
Guangzhou, 510005
China
The latest articles about BNR.
Detailed price information for Burning Rock Biotech Ltd ADR (BNR-Q) from The Globe and Mail including charting and trades.
GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2026. Recent Business Updates Therapy Selection & MRD OncoScreen® BCMatch Tissue Kit has officially entered the Priority Review Channel of the Center for Medical Device Evaluation (
Summary of Jan 6's posts. Generated by AI.
No summary yet.
Summary of Oct 5's posts. Generated by AI.
Summary of Oct 25's posts. Generated by AI.
Investors talking about BNR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.